MCID: OVR060
MIFTS: 33

Ovary Epithelial Cancer

Categories: Cancer diseases, Endocrine diseases, Reproductive diseases

Aliases & Classifications for Ovary Epithelial Cancer

MalaCards integrated aliases for Ovary Epithelial Cancer:

Name: Ovary Epithelial Cancer 12 15
Ovarian Surface Epithelial-Stromal Tumor 12
Epithelial Tumor of Ovary 71

Classifications:



External Ids:

Disease Ontology 12 DOID:2152
NCIt 49 C4381
UMLS 71 C0341823

Summaries for Ovary Epithelial Cancer

Disease Ontology : 12 An ovarian cancer that is derives from ovarian surface epithelium.

MalaCards based summary : Ovary Epithelial Cancer, also known as ovarian surface epithelial-stromal tumor, is related to malignant ovarian surface epithelial-stromal neoplasm and malignant epithelial tumor of ovary. An important gene associated with Ovary Epithelial Cancer is MIR199A1 (MicroRNA 199a-1), and among its related pathways/superpathways are MicroRNAs in cancer and Parkinsons Disease Pathway. The drugs Tranexamic Acid and Hemostatics have been mentioned in the context of this disorder. Affiliated tissues include ovary, bone and liver.

Related Diseases for Ovary Epithelial Cancer

Diseases related to Ovary Epithelial Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 239)
# Related Disease Score Top Affiliating Genes
1 malignant ovarian surface epithelial-stromal neoplasm 32.0 TP53 SERPINA3 MIR509-1 MIR34C MIR30E MIR30C1
2 malignant epithelial tumor of ovary 11.4
3 ovarian squamous cell neoplasm 11.3
4 ovarian mucinous neoplasm 11.3
5 ovarian endometrial cancer 11.3
6 ovarian papillary neoplasm 11.3
7 krukenberg carcinoma 11.3
8 endometriosis of ovary 10.7 MIR30E MIR145 MIR141
9 retinal vascular disease 10.7 MIR30A MIR21 MIR199A1 H2AC18
10 cystadenocarcinoma 10.7 TP53 SERPINA3 MIR30A MIR199A1
11 papillary serous adenocarcinoma 10.7 TP53 MIR30E MIR30A MIR141
12 serous cystadenocarcinoma 10.7 TP53 MIR30A MIR199A1 H2AC18
13 cecal disease 10.7 SERPINA3 H2AC18 CCR6
14 thyroid gland anaplastic carcinoma 10.7 TP53 MIR34C MIR30A MIR17
15 extrinsic cardiomyopathy 10.7 MIR21 ICOSLG H2AC18 CCR6
16 autoimmune disease of skin and connective tissue 10.7 SERPINA3 ICOSLG CCR6
17 listeriosis 10.7 ICOSLG H2AC18 CCR6
18 bacterial infectious disease 10.7 SERPINA3 ICOSLG H2AC18 CCR6
19 herpangina 10.7 TP53 H2AC18 CCR6
20 lichen disease 10.7 TP53 ICOSLG CCR6
21 vaginal disease 10.7 TP53 H2AC18 CCR6
22 mast cell neoplasm 10.7 SERPINA3 ICOSLG H2AC18
23 intrinsic cardiomyopathy 10.7 MIR30A MIR21 MIR199A1 ICOSLG H2AC18
24 coccidiosis 10.7 SERPINA3 ICOSLG H2AC18 CCR6
25 aortic valve disease 2 10.7 SERPINA3 MIR21 MIR199A1 MIR17
26 papillary adenocarcinoma 10.7 TP53 MIR30E MIR30A MIR21 MIR141
27 autoimmune disease of urogenital tract 10.7 ICOSLG H2AC18 CCR6
28 tonsil cancer 10.7 TP53 SERPINA3 MIR199A1 H2AC18
29 thymus gland disease 10.7 TP53 ICOSLG H2AC18 CCR6
30 thymus cancer 10.7 TP53 ICOSLG H2AC18 CCR6
31 neuromuscular junction disease 10.7 SERPINA3 ICOSLG H2AC18 CCR6
32 iga glomerulonephritis 10.7 MIR30A ICOSLG CCR6
33 lipid storage disease 10.7 SERPINA3 MIR199A1 H2AC18 CCR6
34 lymph node disease 10.7 SERPINA3 MIR145 ICOSLG CCR6
35 lymphoma, hodgkin, classic 10.7 MIR30A MIR21 MIR200A ICOSLG CCR6
36 autoimmune disease of endocrine system 10.7 ICOSLG H2AC18 CCR6
37 hypersensitivity reaction type iv disease 10.7 SERPINA3 ICOSLG H2AC18 CCR6
38 respiratory system benign neoplasm 10.7 TP53 MIR30C1 H2AC18
39 anus disease 10.7 TP53 H2AC18 CCR6
40 substance abuse 10.7 SERPINA3 MIR199A1 H2AC18 CCR6
41 lymphadenitis 10.7 SERPINA3 MIR145 ICOSLG CCR6
42 rectal disease 10.7 TP53 H2AC18 CCR6
43 hair disease 10.7 TP53 ICOSLG H2AC18 CCR6
44 monoclonal gammopathy of uncertain significance 10.7 TP53 ICOSLG CCR6
45 blood coagulation disease 10.7 SERPINA3 ICOSLG H2AC18 CCR6
46 mixed cell type cancer 10.7 TP53 SERPINA3 H2AC18
47 thyroid gland papillary carcinoma 10.7 MIR509-1 MIR30E MIR30A MIR200A MIR199A1 MIR17
48 luminal breast carcinoma 10.7 TP53 MIR21 H2AC18
49 chediak-higashi syndrome 10.7 SERPINA3 ICOSLG H2AC18 CCR6
50 parasitic helminthiasis infectious disease 10.7 SERPINA3 MIR21 ICOSLG H2AC18 CCR6

Graphical network of the top 20 diseases related to Ovary Epithelial Cancer:



Diseases related to Ovary Epithelial Cancer

Symptoms & Phenotypes for Ovary Epithelial Cancer

Drugs & Therapeutics for Ovary Epithelial Cancer

Drugs for Ovary Epithelial Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 79)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tranexamic Acid Approved Phase 4 1197-18-8 5526
2 Hemostatics Phase 4
3 Pharmaceutical Solutions Phase 4
4 Antifibrinolytic Agents Phase 4
5 Coagulants Phase 4
6
Parathyroid hormone Approved, Investigational Phase 2 9002-64-6
7
Indinavir Approved Phase 2 150378-17-9 5362440
8
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
9
Fondaparinux Approved, Investigational Phase 2 104993-28-4
10
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
11
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
12
Lenograstim Approved, Investigational Phase 2 135968-09-1
13
Docetaxel Approved, Investigational Phase 1, Phase 2 114977-28-5 148124
14
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
15
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
16
Etoposide Approved Phase 2 33419-42-0 36462
17
Ifosfamide Approved Phase 2 3778-73-2 3690
18
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
19
Melphalan Approved Phase 1, Phase 2 148-82-3 4053 460612
20 Squalamine Investigational Phase 2 148717-90-2
21
Oblimersen Experimental, Investigational Phase 1, Phase 2 190977-41-4
22 Anti-Infective Agents Phase 2
23 Angiogenesis Inhibitors Phase 2
24 Anti-Bacterial Agents Phase 2
25 Antiviral Agents Phase 2
26 Liver Extracts Phase 2
27 Cytochrome P-450 CYP3A Inhibitors Phase 2
28 Cytochrome P-450 Enzyme Inhibitors Phase 2
29 Anti-Retroviral Agents Phase 2
30 Anti-HIV Agents Phase 2
31 Antithrombins Phase 2
32 HIV Protease Inhibitors Phase 2
33 Fibrinolytic Agents Phase 2
34
protease inhibitors Phase 2
35 Serine Proteinase Inhibitors Phase 2
36 Anticoagulants Phase 2
37 Antithrombin III Phase 2
38 PENTA Phase 2
39 Factor Xa Inhibitors Phase 2
40 Protein Kinase Inhibitors Phase 2
41 Imatinib Mesylate Phase 2 220127-57-1 123596
42 Protective Agents Phase 2
43 Immunologic Factors Phase 2
44 Cola Phase 1, Phase 2
45 Immunosuppressive Agents Phase 2
46 Adjuvants, Immunologic Phase 2
47 Alkylating Agents Phase 2
48 Etoposide phosphate Phase 2
49
Isophosphamide mustard Phase 2 0
50 Topoisomerase Inhibitors Phase 2

Interventional clinical trials:

(show all 20)
# Name Status NCT ID Phase Drugs
1 Tranexamic Acid in Surgery of Advanced Ovarian Cancer - a Prospective Randomized Double Blind Placebo Controlled Study Completed NCT00740116 Phase 4 Tranexamic acid;0.9% NaCl solution
2 A Phase IIA Trial of Continuous Five Day Infusions of MSI-1256F (Squalamine Lactate) Plus Carboplatin for Therapy of Refractory and Resistant Stage III and IV Ovarian Cancer Unknown status NCT00021385 Phase 2 carboplatin;squalamine lactate
3 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
4 Women's Cancer Center Protocol #45: Prolonged Venous Thromboembolism Prophylaxis With Fondaparinux in Gynecologic Oncology Patients: An Open Label Phase II Trial Completed NCT00381888 Phase 2 fondaparinux sodium
5 Phase II Clinical Trial With Proteomic Profiling Of Imatinib Mesylate (Gleevec; STI571), A PDGFR And C-Kit Inhibitor, In Patients With Refractory Or Relapsed Epithelial Ovarian Cancer, Fallopian Tube And Primary Peritoneal Cancer Completed NCT00039585 Phase 2 imatinib mesylate
6 Phase II Pilot Study of Clinical Activity and Proteomic Pathway Profiling of the EGFR Inhibitor, ZD1839 (Iressa; Gefitinib), in Patients With Epithelial Ovarian Cancer or Cervical Cancer Completed NCT00049556 Phase 2 gefitinib
7 High Dose Ifosfamide, Carboplatin and Etoposide With Amifostine Chemoprotection Completed NCT00003657 Phase 2 Amifostine;Carboplatin;Etoposide;Ifosfamide
8 Phase I/II Study of Escalating Dose Melphalan With Autologous Pluripotent Hematopoietic Stem Cell Support and Amifostine Cytoprotection in Cancer Patients Completed NCT00003425 Phase 1, Phase 2 amifostine trihydrate;cyclophosphamide;melphalan
9 A Phase I/IIA Dose-Escalating Trial of BCL-2 Antisense (G3139) Treatment for Patients With Androgen-Independent Prostate Cancer or Other Advanced Solid Tumor Malignancies Completed NCT00003103 Phase 1, Phase 2 docetaxel
10 Phase I Study of LMB-9, a Recombinant Disulfide Stabilized Anti-Lewis Y Immunotoxin Admistered by Continuous Infusion Completed NCT00005858 Phase 1
11 Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis Completed NCT00003704 Phase 1 capecitabine
12 Phase I Study Of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion X 10 Days Completed NCT00006981 Phase 1
13 A Phase I Scientific Exploratory Study of Epothilone B Analog in Patients With Solid Tumors and Gynecological Malignancies Completed NCT00005807 Phase 1 BMS-247550
14 A Dose-Escalation Trial Of The Combination Of Docetaxel, Gemcitabine And Filgrastim (NEUPOGEN) For The Treatment Of Patients With Advanced Solid Tumors Completed NCT00014456 Phase 1 docetaxel;gemcitabine hydrochloride
15 A Phase I Study of NX 211 in Combination With Cisplatin Given as an IV Infusion Days 1, 2, and 3 Every 3 Weeks in Patients With Solid Tumors Completed NCT00006036 Phase 1 cisplatin;lurtotecan liposome
16 A Phase I Trial of 17-N-Allylamino-17-Demethoxy Geldanamycin (17-AAG, NSC #330507) Daily X 5 in Patients With Advanced Cancer Therapeutic Protocol Completed NCT00004065 Phase 1 tanespimycin
17 PHASE I STUDY OF TAXOTERE IN PATIENTS WITH ADVANCED MALIGNANCIES AND VARYING DEGREES OF LIVER DYSFUNCTION Completed NCT00002901 Phase 1 docetaxel
18 Phase I Clinical Trial of Oral Suberoylanilide Hydroxamic Acid - SAHA (MSK390) in Patients With Advanced Solid Tumors and Hematologic Malignancies Completed NCT00045006 Phase 1 vorinostat
19 A Study to Determine the Ability of Folate Conjugates to Target Folate Receptors in Ovarian Cancer Tumors Completed NCT00003763
20 Improving Employment Among Gynecologic Cancer Survivors Completed NCT00383279

Search NIH Clinical Center for Ovary Epithelial Cancer

Genetic Tests for Ovary Epithelial Cancer

Anatomical Context for Ovary Epithelial Cancer

MalaCards organs/tissues related to Ovary Epithelial Cancer:

40
Ovary, Bone, Liver, Thyroid, Breast, Skin, Prostate

Publications for Ovary Epithelial Cancer

Articles related to Ovary Epithelial Cancer:

# Title Authors PMID Year
1
Ovarian neoplasms composed of small round cells: a review. 61
15505529 2004

Variations for Ovary Epithelial Cancer

Expression for Ovary Epithelial Cancer

Search GEO for disease gene expression data for Ovary Epithelial Cancer.

Pathways for Ovary Epithelial Cancer

GO Terms for Ovary Epithelial Cancer

Cellular components related to Ovary Epithelial Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.32 SERPINA3 MIR30E MIR30C1 MIR30A MIR29C MIR27A

Biological processes related to Ovary Epithelial Cancer according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.8 TP53 MIR509-1 MIR29C MIR27A MIR21 MIR17
2 negative regulation of angiogenesis GO:0016525 9.76 MIR29C MIR21 MIR193A MIR145
3 transforming growth factor beta receptor signaling pathway GO:0007179 9.74 TP53 MIR30A MIR21
4 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.71 MIR29C MIR21 MIR193A
5 negative regulation of protein kinase B signaling GO:0051898 9.7 MIR34C MIR29C MIR145
6 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.67 MIR27A MIR21 MIR17
7 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.65 MIR29C MIR196A1 MIR193A
8 negative regulation of vascular endothelial cell proliferation GO:1905563 9.61 MIR30E MIR29C MIR193A
9 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.58 MIR27A MIR199A1 MIR17
10 positive regulation of connective tissue replacement GO:1905205 9.56 MIR34C MIR199A1
11 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.56 MIR30E MIR21 MIR199A1 MIR145
12 positive regulation of metalloendopeptidase activity GO:1904685 9.55 MIR21 MIR17
13 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.54 MIR34C MIR199A1 MIR17
14 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.51 MIR21 MIR17
15 gene silencing by miRNA GO:0035195 9.5 MIR509-1 MIR34C MIR30E MIR30C1 MIR30A MIR29C
16 negative regulation of sprouting angiogenesis GO:1903671 9.46 MIR34C MIR30E MIR30C1 MIR17
17 miRNA mediated inhibition of translation GO:0035278 9.35 MIR30A MIR27A MIR21 MIR17 MIR145

Molecular functions related to Ovary Epithelial Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.47 MIR509-1 MIR30E MIR30C1 MIR30A MIR29C MIR27A

Sources for Ovary Epithelial Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....